Loading patent…
AssigneeSamsung Life Public Welfare Foundation
InventorsSeok-Hyung KIM, Do-Hyun NAM, Hyun-Kyu PARK, Kyeung Min JOO, Nam Kyung LEE
Estimating the term…
The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.
An antibody to human c-Met or its antigen-binding fragment, comprising:
An antibody to human c-Met or its antigen-binding fragment, comprising:
An antibody to human c-Met or its antigen-binding fragment, comprising:
A nucleic acid molecule encoding a heavy chain variable region of an antibody cross-reactive to human c-Met and mouse c-Met and including the amino acid sequence of SEQ ID NO:
A nucleic acid molecule encoding a light chain variable region of an antibody cross-reactive to human c-Met and mouse c-Met and including the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.